JP5671475B2 - 方法 - Google Patents

方法 Download PDF

Info

Publication number
JP5671475B2
JP5671475B2 JP2011540202A JP2011540202A JP5671475B2 JP 5671475 B2 JP5671475 B2 JP 5671475B2 JP 2011540202 A JP2011540202 A JP 2011540202A JP 2011540202 A JP2011540202 A JP 2011540202A JP 5671475 B2 JP5671475 B2 JP 5671475B2
Authority
JP
Japan
Prior art keywords
exosomes
cancer
exosome
subject
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011540202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512389A5 (enExample
JP2012512389A (ja
Inventor
アレッド クレイトン，
アレッド クレイトン，
Original Assignee
オックスフォード バイオメディカ （ユーケー） リミテッド
オックスフォード バイオメディカ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード バイオメディカ （ユーケー） リミテッド, オックスフォード バイオメディカ （ユーケー） リミテッド filed Critical オックスフォード バイオメディカ （ユーケー） リミテッド
Publication of JP2012512389A publication Critical patent/JP2012512389A/ja
Publication of JP2012512389A5 publication Critical patent/JP2012512389A5/ja
Application granted granted Critical
Publication of JP5671475B2 publication Critical patent/JP5671475B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2011540202A 2008-12-15 2009-12-15 方法 Expired - Fee Related JP5671475B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0822836.3 2008-12-15
GBGB0822836.3A GB0822836D0 (en) 2008-12-15 2008-12-15 Method
PCT/GB2009/002885 WO2010070276A1 (en) 2008-12-15 2009-12-15 Method

Publications (3)

Publication Number Publication Date
JP2012512389A JP2012512389A (ja) 2012-05-31
JP2012512389A5 JP2012512389A5 (enExample) 2012-11-22
JP5671475B2 true JP5671475B2 (ja) 2015-02-18

Family

ID=40326133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540202A Expired - Fee Related JP5671475B2 (ja) 2008-12-15 2009-12-15 方法

Country Status (6)

Country Link
US (1) US20120027749A1 (enExample)
EP (1) EP2370818A1 (enExample)
JP (1) JP5671475B2 (enExample)
CN (1) CN102301236B (enExample)
GB (1) GB0822836D0 (enExample)
WO (1) WO2010070276A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507300A (ja) 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Ｒｎａパターンを評価する方法
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
US20130052647A1 (en) * 2010-02-10 2013-02-28 Marianna Goldrick Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
KR20140076571A (ko) * 2011-09-22 2014-06-20 유니버시다드 데 로스 안데스 급성 신장 손상의 조기 모니터링, 진단 및/또는 예후 방법
US10254286B2 (en) * 2012-01-24 2019-04-09 Pfizer Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
JP5969777B2 (ja) * 2012-03-07 2016-08-17 国立研究開発法人医薬基盤・健康・栄養研究所 肺腺扁平上皮癌の腫瘍マーカー及び診断キット
SG10201404895XA (en) * 2014-08-13 2016-03-30 Agency Science Tech & Res Diagnosis
CN105388055B (zh) * 2015-12-11 2018-03-27 浙江省肿瘤医院 从尿液中分离肿瘤细胞来源的外泌体的方法
CN105505877B (zh) * 2015-12-11 2018-09-28 浙江省肿瘤医院 恶性胸腔积液中分离肿瘤细胞来源的外泌体的方法
US10874610B2 (en) 2016-10-19 2020-12-29 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
JP7007761B2 (ja) * 2017-09-18 2022-03-04 国立台湾大学 甲状腺癌の予後のためのバイオマーカー
CN115667925A (zh) * 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68923027D1 (de) * 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
EP1354060B1 (en) * 2000-08-28 2011-02-09 Oncomedx, Inc. 5t4 rna in plasma and serum as a marker for neoplastic disease
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
DE102004038076A1 (de) * 2004-02-16 2005-09-01 Proteosys Ag Diagnostische Marker für Krebs
CA2555866A1 (en) * 2004-02-16 2005-08-25 Proteosys Ag Diagnostic markers for cancer
JP2008503498A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 癌の診断及び免疫療法における腫瘍関連抗原プロファイル
CA2578131A1 (en) * 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
EP1724586A3 (en) * 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
AU2009212543B2 (en) * 2008-02-01 2015-07-09 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
GB201018480D0 (en) * 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors

Also Published As

Publication number Publication date
WO2010070276A1 (en) 2010-06-24
US20120027749A1 (en) 2012-02-02
EP2370818A1 (en) 2011-10-05
CN102301236B (zh) 2014-06-25
CN102301236A (zh) 2011-12-28
JP2012512389A (ja) 2012-05-31
GB0822836D0 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
CN102301236B (zh) 方法
Welton et al. Proteomics analysis of bladder cancer exosomes
JP5711196B2 (ja) 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
US9562906B2 (en) Methods for detection of gastric cancer
US20110251097A1 (en) Diagnostic kit of colon cancer using colon cancer related marker and diagnostic method thereof
CN102687011B (zh) 癌症生物标志物及其应用
JP2023510911A (ja) 卵巣癌を検出するための組成物及び方法
WO2022010919A2 (en) Exosomal tumor biomarkers and collections thereof
JP2017133831A (ja) 大腸がんの転移検出方法
AU2009339802A1 (en) RBM3 as a marker for malignant melanoma prognosis
KR101478826B1 (ko) 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트
CN102241772A (zh) 抗体与诊断试剂盒
Dudas et al. Usage of cancer associated autoantibodies in the detection of disease
KR101388711B1 (ko) 암 진단 마커로서의 보체 ｃ９
CN107110848B (zh) 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
KR101680360B1 (ko) Del-1 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물
US20070264643A1 (en) Compositions and Methods Relating to CNS Lymphoma
KR101289454B1 (ko) 소세포폐암 및 비소세포폐암 진단 마커로서의 보체 ｃ９
US11714089B2 (en) Combination of markers for diagnosing cancer
WO2024203968A1 (ja) がんを検出する方法、がんの予後を予測する方法、バイオマーカー及びその使用方法、並びに、がんの検出用又はがんの予後の予測用キット
EP2999967A2 (en) Use of tenascin-c as an extracellular marker of tumor-derived microparticles
WO2011138955A1 (ja) Ｓｉａα２－８Ｓｉａα２－３Ｇａｌβ－Ｒ糖鎖を持つムチン１の分析方法
Risha The proteomic analysis of exosomes from breast cell lines reveals potential biomarkers of breast cancer
KR20160096841A (ko) 간암의 진단 또는 예후 바이오 마커 및 그의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141219

R150 Certificate of patent or registration of utility model

Ref document number: 5671475

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees